CCL18 and interstitial lung disease: Patients who developed PF-ILD had higher serum levels of CCL18 at baseline than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7] ng/mL, p < 0.0001) (Figure 2A).